ZLNA ZELLUNA ASA

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a webcast presentation of its second quarter 2025 results, on Wednesday, August 20, 2025.

The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Wednesday, August 20, 2025. The webcast presentation will be available on the Zelluna website, and it will be possible to post questions during the presentation through the webcast.

The report and presentation will be available on the company website from 07:00 CET the same day.

For further information, please see or contact:

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA

Email: 

Phone:

Hans Vassgård Eid, CFO, Zelluna ASA

Email: 

Phone:



EN
14/08/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna Announces Investor Forum on Science & Strategy to be held on W...

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025 Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at 11:30am CET. Attendance by registration only.  The format will be a panel discussion and open questions and answers (Q&A). The panel will include: Dr. Namir Hassan, CEO, Zelluna ASA, Moderator Prof. Bent Jakob...

September 10, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides...

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today. Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast . Second Quarter 2025 Business Update Highlights On track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026. Broadened regulatory engagement: following positiv...

August 20, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Invitation to Second Quarter 2025 results webcast present...

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a webcast presentation of its second quarter 2025 results, on Wednesday, August 20, 2025. The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Wednesday, August 20, 2025. The webcast presentation will be available on the Zelluna website, and it will be possible to post questions du...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to issue share options to all employees in the Company. A total of 1,634,000 options for shares in the Company have been distributed amongst the employees and two board members. The number of options granted corresponds to 8.0%...

July 3, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Disclosure of share transfer from Inven2 AS

Disclosure of share transfer from Inven2 AS Issuer: Zelluna ASAISIN: NO0013524942Date of transaction: 25 June 2025 Inven2 AS, a major shareholder in Zelluna ASA, has transferred a total of 120,796 shares in Zelluna ASA to two inventors, in accordance with a pre-existing private agreement. Following the transaction, Inven2 AS holds 2,207,033 shares in Zelluna ASA, corresponding to 10.79% of the company’s outstanding shares. Non-Regulatory Press Release

June 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch